Nava Zisapel

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/525533/nava-zisapel-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

41 1,945 21 44 g-index

44 2,245 4 5.53 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
41	Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021 , 60, 252-2	26 ⁷ 1: ² e3	30
40	Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiver's Quality of Life. <i>Journal of Autism and Developmental Disorders</i> , 2019 , 49, 3218-3230	4.6	34
39	New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. <i>British Journal of Pharmacology</i> , 2018 , 175, 3190-3199	8.6	227
38	Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018 , 28, 699-710) ^{2.9}	55
37	Paediatric use of melatonin: Letter to the Editor regarding the manuscript "Current role of melatonin in pediatric neurology:Clinical recommendations" by Bruni etlal. Eur J Paediatr Neurol. 2015 Mar;19(2):122-33. <i>European Journal of Paediatric Neurology</i> , 2017 , 21, 418-419	3.8	3
36	Safety of melatonin. Journal of Paediatrics and Child Health, 2015, 51, 840-1	1.3	2
35	Prolonged release melatonin for improving sleep in totally blind subjects: a pilot placebo-controlled multicenter trial. <i>Nature and Science of Sleep</i> , 2015 , 7, 13-23	3.6	19
34	Current Phase II investigational therapies for insomnia. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 401-11	5.9	14
33	Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial. <i>Clinical Interventions in Aging</i> , 2014 , 9, 947-61	4	93
32	Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 895-905	4	75
31	Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials. <i>Integrated Blood Pressure Control</i> , 2012 , 5, 9-17	3.5	20
30	Drugs for insomnia. Expert Opinion on Emerging Drugs, 2012 , 17, 299-317	3.7	39
29	Prolonged-release melatonin for children with neurodevelopmental disorders. <i>Pediatric Neurology</i> , 2011 , 45, 23-6	2.9	46
28	Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. <i>Vascular Health and Risk Management</i> , 2011 , 7, 577-84	4.4	85
27	Late evening brain activation patterns and their relation to the internal biological time, melatonin, and homeostatic sleep debt. <i>Human Brain Mapping</i> , 2009 , 30, 541-52	5.9	31
26	Low melatonin production in infants with a life-threatening event. <i>Developmental Medicine and Child Neurology</i> , 2007 , 42, 487-491	3.3	
25	Sleep-anticipating effects of melatonin in the human brain. <i>NeuroImage</i> , 2006 , 31, 410-8	7.9	51

(1979-2003)

24	Determination of the minimal clinically significant difference on a patient visual analog sleep quality scale. <i>Journal of Sleep Research</i> , 2003 , 12, 291-8	5.8	67
23	Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. <i>Blood Pressure</i> , 2003 , 12, 19-24	1.7	99
22	Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity. <i>Prostate</i> , 2001 , 49, 145-54	4.2	32
21	Circadian rhythm sleep disorders: pathophysiology and potential approaches to management. <i>CNS Drugs</i> , 2001 , 15, 311-28	6.7	111
20	Melatonin receptors in PC3 human prostate tumor cells. <i>Journal of Pineal Research</i> , 1999 , 26, 211-20	10.4	45
19	Involvement of cGMP in cellular melatonin responses*. <i>Biology of the Cell</i> , 1999 , 91, 45-49	3.5	
18	Cross talk between melatonin and TGFbeta1 in human benign prostate epithelial cells. <i>Prostate</i> , 1999 , 40, 211-7	4.2	13
17	Melatonin receptors in benign prostate epithelial cells: evidence for the involvement of cholera and pertussis toxins-sensitive G proteins in their signal transduction pathways. <i>Prostate</i> , 1998 , 35, 27-34	4.2	16
16	Melatonin replacement therapy of elderly insomniacs. <i>Sleep</i> , 1995 , 18, 598-603	1.1	271
15	Melatonin binding proteins identified in the rat brain by affinity labeling. FEBS Letters, 1991, 288, 105-8	3.8	8
14	Circadian variations in melatonin-binding sites in discrete areas of the male rat brain. <i>FEBS Letters</i> , 1988 , 232, 172-6	3.8	62
13			
	Characterization of central melatonin receptors using 125I-melatonin. FEBS Letters, 1986, 197, 9-12	3.8	72
12	Phorhol actor and calcium act synorgistically to enhance neurotransmitter release by brain neurons	3.8	72 109
12	Phorbol ester and calcium act synergistically to enhance neurotransmitter release by brain neurons		
	Phorbol ester and calcium act synergistically to enhance neurotransmitter release by brain neurons in culture. <i>FEBS Letters</i> , 1985 , 185, 257-61 Calcium-dependent protein phosphorylation and dephosphorylation in intact brain neurons in	3.8	109
11	Phorbol ester and calcium act synergistically to enhance neurotransmitter release by brain neurons in culture. <i>FEBS Letters</i> , 1985 , 185, 257-61 Calcium-dependent protein phosphorylation and dephosphorylation in intact brain neurons in culture. <i>FEBS Letters</i> , 1983 , 156, 257-61 Mechanistic implications of cyanide binding to carboxypeptidase B. <i>International Journal of Peptide</i>	3.8	109
11	Phorbol ester and calcium act synergistically to enhance neurotransmitter release by brain neurons in culture. <i>FEBS Letters</i> , 1985 , 185, 257-61 Calcium-dependent protein phosphorylation and dephosphorylation in intact brain neurons in culture. <i>FEBS Letters</i> , 1983 , 156, 257-61 Mechanistic implications of cyanide binding to carboxypeptidase B. <i>International Journal of Peptide and Protein Research</i> , 1982 , 19, 470-9 Tyrosyl interactions at the active site of carboxypeptidase B. <i>International Journal of Peptide and</i>	3.8	109

6	The reactivity of a functional tyrosyl residue in carboxypeptidase B. Nitration of the cadmium enzyme. <i>FEBS Journal</i> , 1978 , 90, 199-203	5
5	Nuclear-magnetic-resonance studies of carboxypeptidase B. Binding of inhibitors to the manganese enzyme. <i>FEBS Journal</i> , 1975 , 52, 487-92	9
4	On the interaction of esters and peptides with carboxypeptidase B. <i>FEBS Journal</i> , 1975 , 54, 541-7	7
3	Metal-tyrosyl interaction in carboxypeptidases: phosphorescence studies. <i>FEBS Letters</i> , 1975 , 51, 262-5 3.8	5
2	Chemical Approaches to the Mode of Action of Carboxypeptidase B. <i>Israel Journal of Chemistry</i> , 1974 , 12, 631-641	7
1	Interplay between Sex Steroids and Melatonin in Regulation of Human Benign Prostate Epithelial Cell Growth	5